Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers
A glance through the latest expert views and predictions about commodities: lithium outlook remains positive, copper set to decline amid surplus, US steel spreads drop
Brokers remain upbeat on Eclipx Group following FY22 results in line with consensus forecasts
Independent Investment Research updates developments among Australia’s listed investment companies and provides comparative data
Michael Gable of Fairmont Equities notes yesterday saw BHP Group break out of its downtrend, suggesting upside from here
In the face of housing market and inflation concerns, first half results for CSR revealed the benefits of strong cost control and a proactive pricing strategy
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Despite a difficult first quarter, analysts largely expect normalising consumer trends and ongoing inflation to benefit Woolworths in the coming year
The ASX200 gained 6.0% in October after a strong contribution from the banking sector buoyed by a decline in the 10-year bond yield
A mixed bag from IGO’s first quarter update, with strong production from Greenbushes somewhat overshadowed by a significant capital expenditure upgrade for Cosmos
